ONT.L vs PACB
ONT.L: Oxford Nanopore provides portable and scalable DNA and RNA sequencing technology that enables real-time, high-accuracy analysis of genetic material. PACB: PacBio provides high-accuracy, long-read DNA sequencing platforms designed to solve complex genomic challenges for research and clinical applications.
Side-by-side fundamentals
| Metric | ONT.L | PACB | Edge |
|---|---|---|---|
| Price | £2.21 | $2.30 | |
| Market cap | $2.9B | $715M | |
| P/E FY to 2022-12-31, filed 2023-04-26 | 20.05 | n/a | |
| Net margin FY to 2022-12-31, filed 2023-04-26 | -45.8% | n/a | |
| Gross margin FY to 2022-12-31, filed 2023-04-26 | +62.3% | n/a | |
| ROE | -13.1% | -10214.5% | ONT.L higher |
| ROA FY2025, SEC XBRL | n/a | -69.7% | |
| Debt / equity as of 2026-09-02 | n/a | 272.23 | |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +2.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -6.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-02 | n/a | 1.89 | |
| 1-year return | +44.8% | +52.3% | PACB higher |
Fundamentals: SEC XBRL company filings and annual report filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.